Epigenomics' Q1 Revenues Increase 46 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – German molecular diagnostics company Epigenomics reported today that its first-quarter revenues increased 46 percent year over year.

For the three months ended March 31, total revenues were €355,000 ($468,000), up from €243,000 in the first quarter a year ago.

Its product sales increased to €163,000 from €125,000 a year ago, while R&D service income shot up to €126,000 from €4,000. Licensing revenues were down to €66,000 from €114,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.